In many experimental models, including pancreatic [244], bone [243,245], and gastric [246] cancers, the administration of exogenous ENKs (or enkephalinase inhibitors, such as DENKIs), leads to a significant decrease in cancer pain intensity. Here, MME is linked to cancer.